You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma

ID: GL 2-33 juin 2022
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
J. Biagi, R. Cosby, M. Bahl, T. Elfiki, R. Goodwin, J. Hallet, K. Hirmiz, A. Mahmud, the Gastrointestinal Disease Site Group

Guideline Objective:

To make recommendations regarding the adjuvant treatment (adjuvant chemotherapy, adjuvant chemoradiation therapy [CRT] and adjuvant stereotactic body radiation therapy [SBRT]) of patients with resected pancreatic ductal adenocarcinoma (PDAC) with respect to overall survival, progression-free survival, toxicity/safety, and quality of life.

Patient Population:

These recommendations apply to adults with resected PDAC with R0 or R1 margins who are eligible for adjuvant treatment. This guideline does not apply to patients being considered for neoadjuvant therapy of PDAC.

Intended Guideline Users:

The intended users of this guideline are clinicians involved in the delivery of care to patients with resected PDAC.

Research Questions:

This guidance document examines the evidence to answer the following questions:

  1. What is the role of adjuvant chemotherapy in the treatment of patients with resected PDAC with respect to OS, PFS, toxicity/safety and QOL?
  2. What is the role of adjuvant CRT in the treatment of patients with resected PDAC with respect to OS, PFS, toxicity/safety and QOL?
  3. What is the role of adjuvant SBRT in the treatment of patients with resected PDAC with respect to OS, PFS, toxicity/safety and QOL?
pdf download Summary (PDF) (253.33 Ko)
pdf download Full Report (PDF) (706.95 Ko)